A case of ustekinumab-induced sclerouveitis.

Kristen S Godwin, Mariam Mathai, Brian K Do

Open access · goldAbstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

1.0field-weighted citation impact, top 28% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

[Chronic back pain in axial spondylarthritis : Current diagnostic challenges and treatment possibilities].Zeitschrift fur Rheumatologie · 2023
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kristen S GodwinMedstar Georgetown/ Washington Hospital Center Department of Ophthalmology, 110 Irving St NW, Washington, D.C, 20010, USA.

Mariam MathaiThe Retina Group of Washington, 8270 Willow Oaks Corporate Drive, 6th Floor, Fairfax, VA, 22031, USA.

Brian K DoThe Retina Group of Washington, 8270 Willow Oaks Corporate Drive, 6th Floor, Fairfax, VA, 22031, USA.

Elman Retina Group · USWashington Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBiologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-α inhibitors, but there are limited data on ocular side effects associated with the newer generation of biologics. OBSERVATIONS: In this report, we present a case of a suspected ustekinumab-associated recurrent sclerouveitis.

conclusionsTo the best of our knowledge, this is the first reported case of this type seen with ustekinumab injections. Our goal is to add to the existing literature in order to better understand the mechanism and management of this condition.

Indexed as

ScleritisUstekinumabUveitis

Identifiers

PMID35146201

DOI10.1016/j.ajoc.2022.101331

PMCPMC8819278

OpenAlexW4213286138

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.